EZH2 is activated by mutations (gain-of-function) in lymphoma [75], and EZH2 overexpression is associated with aggressiveness and worse clinical outcome in several solid tumors, including prostate, breast, bladder, and endometrial cancers, and melanoma [76–78]. The gene discussed is EZH2; the disease is melanoma.